Therapy Areas: Infectious Diseases
Nabors Named Chief Development Officer at Appili Therapeutics
4 April 2023 - - Nova Scotia, Canada-based biopharmaceutical company Appili Therapeutics Inc. (TSX: APLI) (OTCQB: APLIF) has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili's Chief Development Officer, the company said.

Dr. Nabors joins Appili effective April 3, 2023, and will lead the advancement of programs through development, regulatory submission and key commercialization milestones.

Dr. Nabors joins Appili from Integrated BioTherapeutics Inc. where, in his role as executive vice president and Chief Development Officer, he was responsible for leading the company's vaccine and immunotherapeutic candidates through bioanalytical development, IND-enabling studies, GMP manufacturing and into clinical studies.

Prior to that he served as president of DynPort Vaccine company Inc. (a subsidiary of General Dynamics) where he was responsible for the overall success of the company, overseeing P&L responsibility and 800 staff, and establishing the technical, strategic, and regulatory direction for all projects in the company's portfolio.

Over his accomplished 25-year career, Dr. Nabors has also held progressively senior roles with Sanofi Pasteur, Emergent BioSolutions, and the National Biodefense Analysis and Countermeasures Center (NBACC) within the US Department of Homeland Security.

He has played a central role in product development from pre-clinical stages through to Phase 3, for development of vaccines and therapeutics for pediatric, adult, and biodefense markets.

He has also managed corporate subsidiaries of 120 employees, served on executive-level management committees and presented before Food and Drug Administration advisory committees.

Dr. Nabors will be representing Appili at the World Vaccine Congress, the premier event for R&D and strategic partnering for the global vaccine industry, in Washington, DC, from April 3rd to 6th, 2023.

Dr. Nabors will be participating in scientific sessions to identify current trends in vaccine development and to network with key contacts that Appili may be able to work with to help advance its programs.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections.

By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

The company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections.

Led by a proven management team, Appili is at the epicenter of the global fight against infection.
Login
Username:

Password: